Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record.

Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity

Coburn, Craig A., Meinke, Peter T., Chang, Wei, Fandozzi, Christine M., Graham, Donald J., Hu, Bin, Huang, Qian, Kargman, Stacia, Kozlowski, Joseph, Liu, Rong, McCauley, John A., Nomeir, Amin A., Soll, Richard M., Vacca, Joseph P., Wang, Dahai, Wu, Hao, Zhong, Bin, Olsen, David B., Ludmerer, Steven W.·2013·ChemMedChem

Abstract

The NS5A protein plays a critical role in the replication of HCV and has been the focus of numerous research efforts over the past few years. NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens. Early work in the NS5A arena led to the discovery of our first clinical candidate, MK‐4882 [2‐((S)‐pyrrolidin‐2‐yl)‐5‐(2‐(4‐(5‐((S)‐pyrrolidin‐2‐yl)‐1 H‐imidazol‐2‐yl)phenyl)benzofuran‐5‐yl)‐1 H‐imidazole]. While preclinical proof‐of‐concept studies in HCV‐infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single‐ and multiple‐dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compounds with increased potency against a number of genotypes and NS5A resistance mutations. Modification of the MK‐4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virologic profiles. Herein we describe the research efforts that led to the discovery of MK‐8742, a tetracyclic indole‐based NS5A inhibitor, which is currently in phase 2b clinical trials as part of an all‐oral, interferon‐free regimen for the treatment of HCV infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cmdc.201300343

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 201

Metadata

Authors
Coburn, C. A., Meinke, P. T., Chang, W., Fandozzi, C. M., Graham, D. J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., McCauley, J. A., Nomeir, A. A., Soll, R. M., Vacca, J. P., Wang, D., Wu, H., Zhong, B., Olsen, D. B., & Ludmerer, S. W.
Venue
ChemMedChem
Publisher
Wiley
Published
2013-10-14
Volume
8
Issue
12
Pages
1930-1940
ISSN
  • 1860-7179 (ISSN-L)
  • 1860-7187
OpenAlex
W2020007154
Cited by
201
References
0
FWCI
13.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity. https://app.cochat.ai/papers/10.1002/cmdc.201300343
The paper
Coburn, C. A., Meinke, P. T., Chang, W., Fandozzi, C. M., Graham, D. J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., McCauley, J. A., Nomeir, A. A., Soll, R. M., Vacca, J. P., Wang, D., Wu, H., Zhong, B., Olsen, D. B., & Ludmerer, S. W. (2013). Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity. ChemMedChem. https://doi.org/10.1002/cmdc.201300343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.